TIF Position Statement: Demanding Access To Existing And Upcoming Gene Therapies For β-Thalassaemia

The Thalassaemia International Federation (TIF) is expressing its grave disappointment over the recent announcement of Bluebird Bio regarding the “wind-down” of its operations in Europe and the exclusive disposal of its gene therapy for beta thalassaemia (Zynteglo™) in the United States.

This adverse development has shattered the hope of patients living in Europe and across the world to have access to this long-awaited, one-time and lifelong cure for their disease. It is estimated that over a million patients with thalassaemia across the world, 30,000 of whom live in Europe, are affected by this decision.

Read the Full TIF Position Statement on the Withdrawal of Gene Therapy Zynteglo from Europe HERE